Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1980 May;17(5):871–875. doi: 10.1128/aac.17.5.871

In vitro activities of miconazole, miconazole nitrate, and ketoconazole alone and combined with rifampin against Candida spp. and Torulopsis glabrata recovered from cancer patients.

M R Moody, V M Young, M J Morris, S C Schimpff
PMCID: PMC283890  PMID: 6249197

Abstract

A total of 440 fresh clinical isolates of yeasts from cancer patients were tested by an agar dilution technique against miconazole, miconazole nitrate, and ketoconazole individually and combined with 5 micrograms of rifampin per ml. Most strains of Candida albicans were susceptible to 0.5 microgram or less of the imidazoles per ml. Candida tropicalis required 2 to 4 micrograms of miconazole and its nitrate base per ml for inhibition and was resistant to ketoconazole. The 100% minimal inhibitory concentration of the imidazoles for Candida krusei was 1 microgram/ml. Susceptibility to 4 micrograms of miconazole and miconazole nitrate per ml occurred in 73 and 87% of Torulopsis glabrata strains, respectively, and none was susceptible to ketoconazole. Miconazole was most effective against the Candida spp., whereas its nitrate base was most active against T. glabrata. Synergy was observed when rifampin was combined with miconazole and miconazole nitrate but was not observed when rifampin was combined with ketoconazole. Synergy occurred most frequently when rifampin was combined with miconazole nitrate.

Full text

PDF
871

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anséhn S., Granström S., Höjer H., Nilsson L., Akesson E., Lundin A., Thore A. In-vitro effects of Candida albicans of amphotericin B combined with other antibiotics. Preliminary observations. Scand J Infect Dis Suppl. 1976;(9):62–66. [PubMed] [Google Scholar]
  2. Bannatyne R. M., Cheung R. Susceptibility of Canadida albicans to miconazole. Antimicrob Agents Chemother. 1978 Jun;13(6):1040–1041. doi: 10.1128/aac.13.6.1040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beggs W. H., Sarosi G. A., Andrews F. A. Synergistic action of amphotericin B and rifampin on Candida albicans. Am Rev Respir Dis. 1974 Nov;110(5):671–673. doi: 10.1164/arrd.1974.110.5.671. [DOI] [PubMed] [Google Scholar]
  4. Beggs W. H., Sarosi G. A., Walker M. I. Synergistic action of amphotericin B and rifampin against Candida species. J Infect Dis. 1976 Feb;133(2):206–209. doi: 10.1093/infdis/133.2.206. [DOI] [PubMed] [Google Scholar]
  5. Block E. R., Jennings A. E., Bennett J. E. 5-fluorocytosine resistance in Cryptococcus neoformans. Antimicrob Agents Chemother. 1973 Jun;3(6):649–656. doi: 10.1128/aac.3.6.649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bodey G. P. Fungal infections complicating acute leukemia. J Chronic Dis. 1966 Jun;19(6):667–687. doi: 10.1016/0021-9681(66)90066-x. [DOI] [PubMed] [Google Scholar]
  7. Dixon D., Shadomy S., Shadomy H. J., Espinel-Ingroff A., Kerkering T. M. Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J Infect Dis. 1978 Aug;138(2):245–248. doi: 10.1093/infdis/138.2.245. [DOI] [PubMed] [Google Scholar]
  8. Douglas J. B., Healy J. K. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am J Med. 1969 Jan;46(1):154–162. doi: 10.1016/0002-9343(69)90067-9. [DOI] [PubMed] [Google Scholar]
  9. Fass R. J., Perkins R. L. 5-fluorocytosine in the treatment of cryptococcal and candida mycoses. Ann Intern Med. 1971 Apr;74(4):535–539. doi: 10.7326/0003-4819-74-4-535. [DOI] [PubMed] [Google Scholar]
  10. Fisher J. F., Duma R. J., Markowitz S. M., Shadomy S., Espinel-Ingroff A., Chew W. H. Therapeutic failures with miconazole. Antimicrob Agents Chemother. 1978 Jun;13(6):965–968. doi: 10.1128/aac.13.6.965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Greene W. H., Wiernik P. H. Candida endophthalmitis. Successful treatment in a patient with acute leukemia. Am J Ophthalmol. 1972 Dec;74(6):1100–1104. [PubMed] [Google Scholar]
  12. Holt R. J. Recent developments in antimycotic chemotherapy. Infection. 1974;2(2):95–107. doi: 10.1007/BF01642028. [DOI] [PubMed] [Google Scholar]
  13. Kauffman C. A., Frame P. T. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother. 1977 Feb;11(2):244–247. doi: 10.1128/aac.11.2.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kitahara M., Seth V. K., Medoff G., Kobayashi G. S. Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus. Antimicrob Agents Chemother. 1976 Jun;9(6):915–919. doi: 10.1128/aac.9.6.915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kobayashi G. S., Cheung S. S., Schlessinger D., Medoff G. Effects of rifamycin derivatives, alone and in combination with amphotericin B, against Histoplasma capsulatum. Antimicrob Agents Chemother. 1974 Jan;5(1):16–18. doi: 10.1128/aac.5.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kobbayashi G. S., Medoff G., Schlessinger D., Kwan C. N., Musser W. E. Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science. 1972 Aug 25;177(4050):709–710. doi: 10.1126/science.177.4050.709. [DOI] [PubMed] [Google Scholar]
  17. Levine A. S., Schimpff S. C., Graw R. G., Jr, Young R. C. Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol. 1974 Apr;11(2):141–202. [PubMed] [Google Scholar]
  18. Lou P., Kazdan J., Bannatyne R. M., Cheung R. Successful treatment of Candida endophthalmitis with a synergistic combination of amphotericin B and rifampin. Am J Ophthalmol. 1977 Jan;83(1):12–15. doi: 10.1016/0002-9394(77)90183-0. [DOI] [PubMed] [Google Scholar]
  19. Medoff G., Kobayashi G. S., Kwan C. N., Schlessinger D., Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A. 1972 Jan;69(1):196–199. doi: 10.1073/pnas.69.1.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rifkind D., Crowder E. D., Hyland R. N. In vitro inhibition of Coccidioides immitis strains with amphotericin B plus rifampin. Antimicrob Agents Chemother. 1974 Dec;6(6):783–784. doi: 10.1128/aac.6.6.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Shadomy S. Further in vitro studies with 5-fluorocytosine. Infect Immun. 1970 Oct;2(4):484–488. doi: 10.1128/iai.2.4.484-488.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shadomy S., Paxton L., Espinel-Ingroff A., Shadomy H. J. In vitro studies with miconazole and miconazole nitrate. J Antimicrob Chemother. 1977 Mar;3(2):147–152. doi: 10.1093/jac/3.2.147. [DOI] [PubMed] [Google Scholar]
  23. Stevens D. Miconazole in the treatment of systemic fungal infections. Am Rev Respir Dis. 1977 Nov;116(5):801–806. doi: 10.1164/arrd.1977.116.5.801. [DOI] [PubMed] [Google Scholar]
  24. Sung J. P., Grendahl J. G., Levine H. B. Intravenous and intrathecal miconazole therapy for systemic mycoses. West J Med. 1977 Jan;126(1):5–13. [PMC free article] [PubMed] [Google Scholar]
  25. Van Cutsem J. M., Thienpont D. Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy. 1972;17(6):392–404. doi: 10.1159/000220875. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES